Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry
| Autor: | Lukas, Cédric, Redondin, Manon, Pane, Isabelle, Soubrier, Martin, Houvenagel, Eric, Sibilia, Jean, Combe, Bernard, Morel, Jacques |
|---|---|
| Přispěvatelé: | Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Strasbourg, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Herrada, Anthony |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
MESH: Antirheumatic Agents MESH: Arthritis Rheumatoid MESH: Humans MESH: Registries Immunology MESH: Brain Ischemia Antibodies Monoclonal Humanized MESH: Stroke Brain Ischemia Arthritis Rheumatoid Stroke Cholesterol MESH: Cholesterol Rheumatology [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system MESH: Antibodies Monoclonal Humanized Antirheumatic Agents Immunology and Allergy Humans Female Registries MESH: Female |
| Zdroj: | Clinical and experimental rheumatology Clinical and experimental rheumatology, Clinical and Experimental Rheumatology Sas, 2021, 39 (3), pp.501-507 |
| ISSN: | 0392-856X |
| Popis: | International audience; Objectives: Rheumatoid arthritis (RA) is responsible for excess mortality mainly due to cardiovascular disease. Studies have found elevated cholesterol levels in RA patients who received tocilizumab (TCZ). We studied the occurrence of major cardiovascular events in RA patients who received TCZ in current practice. We also analysed cholesterol level changes in these patients.Methods: Data were collected from the French REGATE Registry, a multicentre observational study including patients with RA treated with TCZ. All cardiovascular complications were analysed. Changes in cholesterol levels were studied. Factors associated with major adverse cardiac and cerebrovascular events were analysed by multivariate analysis, estimating odds ratios and 95% confidence intervals.Results: During an exposure time of 5591 patient-years (PYs), 35 cardiovascular events occurred in 33 patients, corresponding to an incidence of 0.63/100 PYs. The incidence of ischaemic stroke and cardiac ischaemia was 0.41 and 0.21/100 PYs. Age and personal history of cardiovascular events were identified as risk factors associated with cardiovascular events: OR=1.06 [95% CI 1.02-1.09] and 4.10 [1.90-8.83]. Female sex was a protective factor (OR=0.29 [95% CI 0.14-0.64]). Glucocorticoids may play a role but was not statistically significant. All cholesterol variables were increased in level after the third month of treatment with TCZ, with a 15.4%, 18.9% and 13.4% increase for total cholesterol, LDL-C and HDL-C, at 3 months.Conclusions: In current practice, cardiovascular events occurring under TCZ treatment is in the range of what is expected in RA patients despite a global increase in cholesterol levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|